Collaboration bridges AI design and viral vector validation

A new collaboration between Applied Biopharm Consulting and the Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) at South East Technological University is set to support the experimental validation of AI-driven approaches to viral vector engineering.

The partnership will use cell-based studies to generate data that complements a computational biomolecular research programme focused on viral vector design for advanced biologics and gene therapy applications. The work is supported through the Enterprise Ireland Innovation Voucher scheme, enabling access to specialist academic laboratory expertise.

The initiative reflects a broader trend in biopharmaceutical R&D, where computational modelling and artificial intelligence are increasingly being combined with experimental systems to improve the design and understanding of complex biologics.

At the centre of the programme is the use of AI-based analysis of protein structures and molecular interactions to explore new strategies for viral vector development. These computational outputs will then be tested and refined through laboratory-based validation.

The collaboration builds on previous funding awarded under Enterprise Ireland schemes and forms part of an ongoing effort to translate early-stage computational research into experimentally validated technologies with potential application in gene therapy development.

Dr Anthony Newcombe, Managing Director of Applied Biopharm Consulting Ltd, said: “This collaboration marks an important step in moving our viral vector engineering programme from computational design towards experimental validation, supported by access to specialist academic expertise.”

Dr Niall O'Reilly, Centre Director of the PMBRC added: “This partnership highlights the value of academia–industry collaboration in translating innovative ideas into experimentally validated technologies in areas such as gene therapy and biomedical science.”

Alongside its research activities, the consultancy continues to support biopharmaceutical companies in GMP compliance, regulatory affairs and manufacturing science, positioning its work at the interface of advanced therapy development and bioprocess innovation.

More information online